Twist Bioscience Corp. Stock Analysis TWST

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 979 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The company has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The firm also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The firm's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. The company has minority ownership in Atlas Data Storage, Inc.